Considered the well-known metabolic routes of sofosbuvir [14,15], to better understand the impact of NAFLD on the metabolism and activation of this drug, we measured the mRNA expression of the two enzymes involved in the synthesis of the active triphosphate drug GS-330117-TP, i.e., UMP-CMPK1 and ND-PK, and the protein expression of UMP-CMPK1. The gene discussed is CMPK1; the disease is metabolic dysfunction-associated steatotic liver disease.